Healthcare / Medical DistributionTaiwan
$28.55
+0.45 (+1.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $129.1M · quality 37.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.6B
P/E
28.6x
↑EV/EBITDA
8.5x
↓ROE
2.4%
↑Gross Margin
26.1%
↓Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.9%
FCF CAGR
—
FCF margin
2.9%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.40B · net income $186.3M · FCF $129.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.40B | $4.40B | $3.60B | $3.88B | $2.97B |
| Net Income | $186.3M | $186.3M | $168.4M | $418.9M | $356.6M |
| EBITDA | $1.09B | $1.09B | $955.3M | $1.24B | $1.05B |
| EPS | — | — | 0.98 | 2.26 | 1.98 |
| Gross Margin | 26.1% | 26.1% | 21.1% | 27.6% | 30.3% |
| Operating Margin | 9.3% | 9.3% | 6.6% | 15.8% | 16.1% |
| Net Margin | 4.2% | 4.2% | 4.7% | 10.8% | 12.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 0.91 | 0.81 | 0.82 |
| Current Ratio | 1.77 | 1.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $129.1M | $129.1M | $-331.7M | $386.9M | $-26.0M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 2.7% | 6.5% | 5.8% |
| Valuation | |||||
| P/E | 28.55 | 28.55 | 42.65 | 26.64 | 22.27 |
| EV/EBITDA | 8.47 | 8.47 | 12.81 | 12.04 | 11.40 |
| P/B | 0.73 | 0.73 | 1.29 | 1.80 | 1.38 |
| Growth & Yield | |||||
| Revenue Growth | 22.2% | 22.2% | -7.1% | 30.4% | — |
| EPS Growth | — | — | -56.6% | 14.1% | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.98 → n/d
Residual
-31.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.